Olympus boss Bob White adopts private equity tactics to revive the medical imaging maker, cutting 2,000 jobs, overhauling regional setup, selling assets, aiming to pre‑empt takeover bids. The 107‑year‑old firm, dominant in medical endoscopes, faces a 15% share drop over two years due to US regulatory issues and scandals including accounting fraud uncovered by former CEO Michael Woodford and the illegal drug charges that forced out Stefan Kaufmann. Its market value is ¥2.3tn ($14.7bn).

Private equity firms have informally approached but no offers yet. Strong Q1 results lifted shares, yet analysts doubt sustainability, noting competition in North America. White’s strategic review of surgical endoscopy and cultural shift aim to align with FDA demands, while analysts see a break from insular leadership.

Defiance continues as any takeover would be politically sensitive in Japan, where Olympus remains a national icon. White, a Medtronic veteran, says "I say operate as if they sit at the table," emphasizing use of private equity playbook. The company’s defence options are under consideration, and the heart of Olympus, he insists, will stay in Japan.